A simple view on lung cancer biology: The MET pathway

被引:5
作者
Ruppert, A. -M. [1 ]
Beau-Faller, M. [2 ]
Belmont, L. [1 ]
Lavole, A. [1 ]
Gounant, V. [1 ]
Cadranel, J. [1 ,3 ]
Wislez, M. [1 ,3 ]
机构
[1] Hop Tenon, AP HP, Serv Pneumol & Reanimat, F-75970 Paris 20, France
[2] Hop Univ Strasbourg, Hop Hautepierre, Serv Biochim & Biol Mol, F-67200 Strasbourg, France
[3] Univ Paris 06, Equipe Rech 2, F-75970 Paris 20, France
关键词
MET; Non small lung cancer; Prognosis; Biomarker; Tyrosine kinase receptor; Tyrosine kinase inhibitor; HEPATOCYTE GROWTH-FACTOR; GENE COPY NUMBER; RECEPTOR TYROSINE KINASE; C-MET; CARCINOMA CELLS; EXPRESSION; ADENOCARCINOMA; ACTIVATION; MUTATIONS; TUMORIGENICITY;
D O I
10.1016/j.rmr.2011.05.014
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
MET is a cell membrane tyrosine kinase receptor for its ligand the hepatocyte growth factor (HGF), also called scatter factor (SF). MET conveys mitogenic, motogenic and proangiogenic signals, important during embryonic development and during the development of cancer. Activation of the HGF-MET pathway seems to be associated with a poor prognosis in lung cancer. Activation in lung cancer may be related to several molecular anomalies: ligand overexpression, receptor overexpression, genomic amplification or MET mutation. In MET amplified or mutated lung cancer, MET may be an important oncogene, as the tumor appears "MET addicted". In other lung cancers, MET may be implicated in tumour progression by tissue invasion and formation of metastases. MET amplification is also a mechanism known to be implicated in 20% of secondary resistance to EGFR inhibitors in patients presenting EGFR mutated lung cancer. Different strategies of MET inhibition in lung cancer are being studied, particularly in EGFR mutated lung cancer. In this review we discuss the structure of the MET receptor, the activated pathways, the main genomic anomalies in lung cancer and the development of MET inhibitors. (C) 2011 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1241 / 1249
页数:9
相关论文
共 50 条
  • [31] The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Non-small-Cell Lung Cancer
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Rossi, Antonio
    Rossi, Emanuela
    Napolitano, Alba
    Palazzolo, Giovanni
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Ciardiello, Fortunato
    Gridelli, Cesare
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (37) : 6155 - 6168
  • [32] Targeting the c-MET signaling pathway for cancer therapy
    Liu, Xiangdong
    Yao, Wenqing
    Newton, Robert C.
    Scherle, Peggy A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 997 - 1011
  • [33] Differential role of MACC1 expression and its regulation of the HGF/c-Met pathway between breast and colorectal cancer
    Sueta, Aiko
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Hayashi, Mitsuhiro
    Takeshita, Takashi
    Yamamoto, Satoko
    Omoto, Yoko
    Iwase, Hirotaka
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (05) : 2143 - 2153
  • [34] MicroRNA-409-3p Functions as a Tumor Suppressor in Human Lung Adenocarcinoma by Targeting c-Met
    Wan, Li
    Zhu, Lingjun
    Xu, Jianghao
    Lu, Binbin
    Yang, Yucai
    Liu, Fengzhen
    Wang, Zhaoxia
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 34 (04) : 1273 - 1290
  • [35] MET-inhibitors meet MET mutations in lung cancer
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1248 - S1254
  • [36] MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
    Zhou, Jian-Ya
    Chen, Xi
    Zhao, Jing
    Bao, Zhang
    Chen, Xing
    Zhang, Pei
    Liu, Zhen-Feng
    Zhou, Jian-Ying
    CANCER LETTERS, 2014, 351 (02) : 265 - 271
  • [37] MET in gastric cancer - discarding a 10% cutoff rule
    Metzger, Marie-Luise
    Behrens, Hans-Michael
    Boeger, Christine
    Haag, Jochen
    Krueger, Sandra
    Roecken, Christoph
    HISTOPATHOLOGY, 2016, 68 (02) : 241 - 253
  • [38] MET amplification as a potential therapeutic target in gastric cancer
    Kawakami, Hisato
    Okamoto, Isamu
    Arao, Tokuzo
    Okamoto, Wataru
    Matsumoto, Kazuko
    Taniguchi, Hirokazu
    Kuwata, Kiyoko
    Yamaguchi, Haruka
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Yamada, Yasuhide
    ONCOTARGET, 2013, 4 (01) : 9 - 17
  • [39] Clinical implications of MET gene copy number in lung cancer
    Toschi, Luca
    Cappuzzo, Federico
    FUTURE ONCOLOGY, 2010, 6 (02) : 239 - 247
  • [40] MEK inhibitors against MET-amplified non-small cell lung cancer
    Chiba, Masato
    Togashi, Yosuke
    Tomida, Shuta
    Mizuuchi, Hiroshi
    Nakamura, Yu
    Banno, Eri
    Hayashi, Hidetoshi
    Terashima, Masato
    De Velasc, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Mitsudomi, Tetsuya
    Nishio, Kazuto
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2236 - 2244